The Pro Medicus Limited (ASX:PME) share price has been a strong performer on Thursday. Here’s why its shares are charging higher…
The post Here’s why the Pro Medicus (ASX:PME) share price is charging higher appeared first on The Motley Fool Australia. –
The Pro Medicus Limited (ASX: PME) share price has been a strong performer on Thursday.
In early trade, the health imaging company’s shares were up as much as 5% to $43.44.
The Pro Medicus share price has pulled back a touch since then but remains up 3% to $42.61 currently.
Why is the Pro Medicus share price charging higher?
Investors have been buying the company’s shares after it provided an update on its share buyback.
One year ago, Pro Medicus commenced an on-market share buyback for a period of 12 months. This allowed the company to buy back up to 10% of its shares on issue over the period.
However, this buyback has now completed without the purchase of a single share.
The good news for shareholders is that in light of its failure to buy shares over the last 12 months, the Pro Medicus board has announced the commencement of a new on-market share buyback today.
Once again, this will run for a period of 12 months and allows the company to acquire up to 10% of its shares on issue. This buyback program will commence in approximately 14 days and be handled by Goldman Sachs Australia.
Will Pro Medicus buy shares this time?
It remains unclear at what level the Pro Medicus share price would have to be trading at for the company to begin buying shares.
However, with its shares trading within sight of its all-time high, it seems unlikely that Goldman Sachs will be buying shares in the near term. Particularly given how they were trading below $30.00 for much of last year when its previous buyback program was in place.
Though, it is also worth noting that Goldman currently has a buy rating and $53.80 price target on the company’s shares. So clearly its analysts see a lot of value in them at the current level.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- 2 exciting ASX growth shares to buy next month
- 2 strong ASX mid cap shares to buy
- 2 ASX shares delivering irresistible growth
- 3 ASX Healthcare shares feeling a little under the weather
- The Pro Medicus (ASX:PME) share price is up 23% in 2021: Can it go higher?
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.